317 related articles for article (PubMed ID: 24195695)
1. Valsartan slows the progression of diabetic nephropathy in db/db mice via a reduction in podocyte injury, and renal oxidative stress and inflammation.
Zhou G; Cheung AK; Liu X; Huang Y
Clin Sci (Lond); 2014 May; 126(10):707-20. PubMed ID: 24195695
[TBL] [Abstract][Full Text] [Related]
2. A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy.
Huang Y; Border WA; Yu L; Zhang J; Lawrence DA; Noble NA
J Am Soc Nephrol; 2008 Feb; 19(2):329-38. PubMed ID: 18216319
[TBL] [Abstract][Full Text] [Related]
3. Protective effects of aliskiren and valsartan in mice with diabetic nephropathy.
Wang W; Qiu L; Howard A; Solis N; Li C; Wang X; Kopp JB; Levi M
J Renin Angiotensin Aldosterone Syst; 2014 Dec; 15(4):384-95. PubMed ID: 25031296
[TBL] [Abstract][Full Text] [Related]
4. Targeting reduction of proteinuria in glomerulonephritis: Maximizing the antifibrotic effect of valsartan by protecting podocytes.
Gu C; Zhou G; Noble NA; Border WA; Cheung AK; Huang Y
J Renin Angiotensin Aldosterone Syst; 2014 Jun; 15(2):177-89. PubMed ID: 23223090
[TBL] [Abstract][Full Text] [Related]
5. A plasminogen activator inhibitor type 1 mutant retards diabetic nephropathy in db/db mice by protecting podocytes.
Zhang J; Gu C; Lawrence DA; Cheung AK; Huang Y
Exp Physiol; 2014 May; 99(5):802-15. PubMed ID: 24443353
[TBL] [Abstract][Full Text] [Related]
6. An additive effect of anti-PAI-1 antibody to ACE inhibitor on slowing the progression of diabetic kidney disease.
Gu C; Zhang J; Noble NA; Peng XR; Huang Y
Am J Physiol Renal Physiol; 2016 Nov; 311(5):F852-F863. PubMed ID: 27511457
[TBL] [Abstract][Full Text] [Related]
7. Effects of mycophenolate mofetil, valsartan and their combined therapy on preventing podocyte loss in early stage of diabetic nephropathy in rats.
Zhang Y; Chen B; Hou XH; Guan GJ; Liu G; Liu HY; Li XG
Chin Med J (Engl); 2007 Jun; 120(11):988-95. PubMed ID: 17624267
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of aliskiren, compared with angiotensin II blockade, in slowing the progression of diabetic nephropathy in db/db mice: should the combination therapy be a focus?
Zhou G; Liu X; Cheung AK; Huang Y
Am J Transl Res; 2015; 7(5):825-40. PubMed ID: 26175845
[TBL] [Abstract][Full Text] [Related]
9. Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes.
Tang L; Wu Y; Tian M; Sjöström CD; Johansson U; Peng XR; Smith DM; Huang Y
Am J Physiol Endocrinol Metab; 2017 Nov; 313(5):E563-E576. PubMed ID: 28811292
[TBL] [Abstract][Full Text] [Related]
10. Podocyte-specific Nox4 deletion affords renoprotection in a mouse model of diabetic nephropathy.
Jha JC; Thallas-Bonke V; Banal C; Gray SP; Chow BS; Ramm G; Quaggin SE; Cooper ME; Schmidt HH; Jandeleit-Dahm KA
Diabetologia; 2016 Feb; 59(2):379-89. PubMed ID: 26508318
[TBL] [Abstract][Full Text] [Related]
11. Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin.
Davis BJ; Cao Z; de Gasparo M; Kawachi H; Cooper ME; Allen TJ
J Hypertens; 2003 Jan; 21(1):209-16. PubMed ID: 12544453
[TBL] [Abstract][Full Text] [Related]
12. The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat.
Habibi J; Aroor AR; Das NA; Manrique-Acevedo CM; Johnson MS; Hayden MR; Nistala R; Wiedmeyer C; Chandrasekar B; DeMarco VG
Cardiovasc Diabetol; 2019 Mar; 18(1):40. PubMed ID: 30909895
[TBL] [Abstract][Full Text] [Related]
13. Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy.
Barutta F; Piscitelli F; Pinach S; Bruno G; Gambino R; Rastaldi MP; Salvidio G; Di Marzo V; Cavallo Perin P; Gruden G
Diabetes; 2011 Sep; 60(9):2386-96. PubMed ID: 21810593
[TBL] [Abstract][Full Text] [Related]
14. Probucol inhibited Nox2 expression and attenuated podocyte injury in type 2 diabetic nephropathy of db/db mice.
Zhou G; Wang Y; He P; Li D
Biol Pharm Bull; 2013; 36(12):1883-90. PubMed ID: 24432375
[TBL] [Abstract][Full Text] [Related]
15. Sulodexide ameliorates early but not late kidney disease in models of radiation nephropathy and diabetic nephropathy.
Rossini M; Naito T; Yang H; Freeman M; Donnert E; Ma LJ; Dunn SR; Sharma K; Fogo AB
Nephrol Dial Transplant; 2010 Jun; 25(6):1803-10. PubMed ID: 20061322
[TBL] [Abstract][Full Text] [Related]
16. The effects of angiotensin-II receptor blockers on podocyte damage and glomerular apoptosis in a rat model of experimental streptozotocin-induced diabetic nephropathy.
Tunçdemir M; Oztürk M
Acta Histochem; 2011 Dec; 113(8):826-32. PubMed ID: 21269661
[TBL] [Abstract][Full Text] [Related]
17. [The effects of VEGF-R inhibitor on podocytopathy of rats with type I diabetic nephropathy].
Wang S; Li Y; Huang YJ
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2011 Sep; 27(9):1003-6. PubMed ID: 21906476
[TBL] [Abstract][Full Text] [Related]
18. Dual blockade of the homeostatic chemokine CXCL12 and the proinflammatory chemokine CCL2 has additive protective effects on diabetic kidney disease.
Darisipudi MN; Kulkarni OP; Sayyed SG; Ryu M; Migliorini A; Sagrinati C; Parente E; Vater A; Eulberg D; Klussmann S; Romagnani P; Anders HJ
Am J Pathol; 2011 Jul; 179(1):116-24. PubMed ID: 21703397
[TBL] [Abstract][Full Text] [Related]
19. Schisandra chinensis fruit extract attenuates albuminuria and protects podocyte integrity in a mouse model of streptozotocin-induced diabetic nephropathy.
Zhang M; Liu M; Xiong M; Gong J; Tan X
J Ethnopharmacol; 2012 May; 141(1):111-8. PubMed ID: 22353431
[TBL] [Abstract][Full Text] [Related]
20. Selective phosphodiesterase-5 (PDE-5) inhibitor vardenafil ameliorates renal damage in type 1 diabetic rats by restoring cyclic 3',5' guanosine monophosphate (cGMP) level in podocytes.
Fang L; Radovits T; Szabó G; Mózes MM; Rosivall L; Kökény G
Nephrol Dial Transplant; 2013 Jul; 28(7):1751-61. PubMed ID: 23203993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]